Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methoxyphenylacetonitrile SCHEMBL103029 | 0.85 | PKM (0.61) | PKMFLT3KMT2ANPC1RAB9A | |
| 3-Methoxyphenylacetonitrile SCHEMBL27728444 | 0.83 | PKM (0.59) | PKMFLT3KMT2ANPC1RAB9A | |
| 3-Methoxyphenylacetonitrile SCHEMBL29253102 | 0.83 | PKM (0.59) | PKMFLT3KMT2ANPC1RAB9A | |
| 3-Methoxyphenylacetonitrile SCHEMBL28155308 | 0.82 | PKM (0.58) | PKMFLT3SMN1; SMN2IDO1GAA | |
| SCHEMBL8992958 | 0.80 | LTA4H (0.59) | PKMFLT3KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5004118 | 0.80 | FLT3 (0.57) | PKMFLT3KMT2AMEN1POLB | |
| 3-Methoxyphenylacetonitrile SCHEMBL7135147 | 0.78 | LTA4H (0.62) | PKMFLT3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11532120 | 0.76 | L3MBTL1 (0.49) | PKMFLT3KMT2AMEN1TDP1 | |
| SCHEMBL6933353 | 0.76 | PKM (0.52) | PKMFLT3KMT2ANPC1RAB9A | |
| SCHEMBL3520397 | 0.76 | APP (0.61) | PKMNPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138226-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234257-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | PKM 823/4885FLT3 4497/4885KMT2A 4413/4885 |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | PKM 823/4885FLT3 4497/4885KMT2A 4413/4885 |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | SLC6A4, HTR4, OPRK1 | PKM 1028/4885FLT3 3072/4885KMT2A 4617/4885 |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | PKM 823/4885FLT3 4497/4885KMT2A 4413/4885 |
| US-20080234257-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | PKM 1003/4885FLT3 4309/4885KMT2A 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.